Peizhi Luo
Algemeen Directeur bij ADAGENE INC.
Vermogen: 22 M $ op 30-04-2024
Actieve functies van Peizhi Luo
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ADAGENE INC. | Algemeen Directeur | 01-11-2011 | - |
Voorzitter | 01-02-2018 | - | |
Hoofd Techniek/Wetenschap/O&O | - | - | |
Oprichter | 25-02-2011 | - |
Loopbaan van Peizhi Luo
Eerdere bekende functies van Peizhi Luo
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Abmaxis, Inc.
Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Directeur/Bestuurslid | 01-01-2000 | 06-11-2008 |
Hoofd Techniek/Wetenschap/O&O | 01-01-2000 | 06-11-2008 | |
Oprichter | 01-01-2000 | 06-11-2008 | |
President | 01-01-2000 | 06-11-2008 | |
XENCOR, INC. | Corporate Officer/Principal | 01-07-1998 | 01-08-2000 |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Opleiding van Peizhi Luo
The University of Chicago | Doctorate Degree |
Peking University | Undergraduate Degree |
Chinese Academy of Sciences | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
China | 4 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
ADAGENE INC. | Health Technology |
XENCOR, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Abmaxis, Inc.
Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Health Technology |
- Beurs
- Insiders
- Peizhi Luo
- Ervaring